Compile Data Set for Download or QSAR
Report error Found 106 Enz. Inhib. hit(s) with all data for entry = 9562
TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474403(US10858373, Example 1 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 0.259nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474408(US10858373, Example 6 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 0.470nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474444(US10858373, Example 42)
Affinity DataIC50: 0.587nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474454(US10858373, Example 52)
Affinity DataIC50: 0.666nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474429(US10858373, Example 27)
Affinity DataIC50: 0.679nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474416(US10858373, Example 14 | 1,1,1,3,3,3-Hexafluoropro...)
Affinity DataIC50: 0.942nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474404(US10858373, Example 2 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 1nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474434(US10858373, Example 32)
Affinity DataIC50: 1.08nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474435(US10858373, Example 33)
Affinity DataIC50: 1.21nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474443(US10858373, Example 41)
Affinity DataIC50: 1.25nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474442(US10858373, Example 40)
Affinity DataIC50: 1.43nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474451(US10858373, Example 49)
Affinity DataIC50: 1.45nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474440(US10858373, Example 38)
Affinity DataIC50: 2.19nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474430(US10858373, Example 28)
Affinity DataIC50: 2.22nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474433(US10858373, Example 31)
Affinity DataIC50: 2.26nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474413(US10858373, Example 11 | 1,1,1,3,3,3-Hexafluoropro...)
Affinity DataIC50: 2.46nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474452(US10858373, Example 50)
Affinity DataIC50: 2.46nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474438(US10858373, Example 36)
Affinity DataIC50: 2.79nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474439(US10858373, Example 37)
Affinity DataIC50: 3.03nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474403(US10858373, Example 1 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 3.09nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474410(US10858373, Example 8 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 3.29nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474416(US10858373, Example 14 | 1,1,1,3,3,3-Hexafluoropro...)
Affinity DataIC50: 3.63nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474441(US10858373, Example 39)
Affinity DataIC50: 4.04nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474408(US10858373, Example 6 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 4.39nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474414(US10858373, Example 12 | 1,1,1,3,3,3-Hexafluoropro...)
Affinity DataIC50: 4.90nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474444(US10858373, Example 42)
Affinity DataIC50: 4.93nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474429(US10858373, Example 27)
Affinity DataIC50: 6.25nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474417(US10858373, Example 15)
Affinity DataIC50: 7.86nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474404(US10858373, Example 2 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 7.94nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474454(US10858373, Example 52)
Affinity DataIC50: 8.04nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474451(US10858373, Example 49)
Affinity DataIC50: 8.34nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474405(US10858373, Example 3 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 8.49nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474455(US10858373, Example 53)
Affinity DataIC50: 10.1nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474430(US10858373, Example 28)
Affinity DataIC50: 10.3nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474418(US10858373, Example 16)
Affinity DataIC50: 10.4nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474419(US10858373, Example 17)
Affinity DataIC50: 10.5nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474443(US10858373, Example 41)
Affinity DataIC50: 12nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474434(US10858373, Example 32)
Affinity DataIC50: 13.7nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474420(US10858373, Example 18)
Affinity DataIC50: 14nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474435(US10858373, Example 33)
Affinity DataIC50: 15nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474409(US10858373, Example 7 | N-[(3R)-8-{[(2,5-Dioxopyrr...)
Affinity DataIC50: 15.6nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474413(US10858373, Example 11 | 1,1,1,3,3,3-Hexafluoropro...)
Affinity DataIC50: 17.6nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474452(US10858373, Example 50)
Affinity DataIC50: 19nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474406(US10858373, Example 4)
Affinity DataIC50: 20.3nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474433(US10858373, Example 31)
Affinity DataIC50: 20.8nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474440(US10858373, Example 38)
Affinity DataIC50: 22nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474442(US10858373, Example 40)
Affinity DataIC50: 22.9nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474449(US10858373, Example 47)
Affinity DataIC50: 23nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474439(US10858373, Example 37)
Affinity DataIC50: 25.8nMAssay Description:Assessment of MAGL inhibition utilizes human recombinant Monoacylglycerol Lipase and the fluorogenic substrate 7-hydroxycoumarinyl arachidonate (7-HC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Pfizer

US Patent
LigandPNGBDBM474421(US10858373, Example 19)
Affinity DataIC50: 28.5nMAssay Description:T = 30 minutes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 106 total ) | Next | Last >>
Jump to: